[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-biopsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-biopsy":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100552427","non-invasive-evaluation-of-graft-condition-in-adult-patients-with-kidney-transplant-using-ultrasound-localization-microscopy-and-multispectral-optoacoustic-tomography-100552427",false,"NCT06472947","Non-invasive Evaluation of Graft Condition in Adult Patients With Kidney Transplant Using Ultrasound Localization Microscopy and Multispectral Optoacoustic Tomography","ESTIMATOR","Inclusion Criteria:\n\n* kidney transplant\n* indication for biopsy set in clinical routine\n* minimum 18 years of age\n* written consent\n\nExclusion Criteria:\n\n* allergy against contrast agents\u002F SonoVue\n* tatoos in examined areas\n* contraindication against SonoVue\n* pregnant women\n* breast feeding women","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","OBSERVATIONAL","In this study, the condition of the kidney transplant in adults is to be assessed non-invasively using Multispectral Optoacoustic Tomography and Ultrasound Localization Microscopy (ULM). ULM imaging can be performed in a 2-dimensional and a 3-dimensional way (2D and 3D ULM). Therefore, \"ULM\" in the following texts and measures will refer to 2D and 3D ULM.\n\nNew, non-invasive markers that allow conclusions to be drawn about the condition of the transplant should reduce the need for invasive diagnostic procedures in the future.",[24,25],"Kidney Transplant","Kidney Biopsy","RECRUITING","2026-03-02",{"date":29,"type":30},"2026-03-04","ACTUAL",{"date":32,"type":30},"2024-06-18",{"date":34,"type":20},"2028-01-18",{"name":36,"class":37},"University of Erlangen-Nürnberg Medical School","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":58,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100432824","diabetic-nephropathy-in-people-with-diabetes-prevalence-and-predictive-factors-100432824","NCT04916132","Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors","Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors","PRIMETIME2","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Diagnosis with T2DM according to the American diabetes Association (20)\n* eGFR \\>30 mL\u002Fmin\u002F1.73 m2 (maximum six months old)\n* urine-albumin\u002Fcreatinine-ratio (uACR) \\> 700 mg\u002Fg or 24 hours urine albumin \\>700 mg on more than one measurement\n\nExclusion Criteria:\n\n* Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy\n* Factors that increases the risk of complications due to kidney biopsy:\n\n  * Hemoglobin \\\u003C 6 mmol\u002FL\n  * INR \\>1,4 at the time for biopsy\n  * Platelet count \\\u003C 100 x 109\u002Fl\n  * Uncontrolled high blood pressure (defined as systolic blood pressure \\> 160 mmHg and\u002For diastolic blood pressure \\> 100 mmHg)\n  * Only one functioning kidney\n  * Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy\n  * Multiple bilateral kidney cysts\n  * Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy\n  * Unwilling to receive blood transfusion\n  * Unable to lie flat in bed six hours after biopsy\n  * Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines\n* Unable to understand written and oral information\n* Kidney transplant recipient\n* Previous medical kidney biopsy\n* Women who are pregnant or planning to become pregnant before the kidney biopsy is performed\n* Treatment with Marcoumar (all other anticoagulants are accepted)\n* High thromboembolic risk combined with held in anticoagulation therapy according to the report \"Perioperative regulation of antithrombotic treatment\" (PRAB) (22)\n\n  * mechanical heart valve\n  * atrial fibrillation AND CHA2DS2-VASc\\> 5 and\u002For stroke within the last three months\n  * recurrent venous thromboembolism OR venous thromboembolism within the last three months\n  * less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG))\n  * less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES))\n  * less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis)\n  * less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG)\n  * less than 3 months after revascularization in individuals with stable CAD (PCI with DES)\n  * less than 3 months after stroke, or Transient Ischemic Attack (TIA)\n* Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy\n\nIf a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.","120 Years",{"count":49,"type":20},300,"a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.",[52,53,54,55,56,57,25],"Chronic Kidney Diseases","Albuminuria","Diabetic Kidney Disease","Diabetic Nephropathies","Diabetes type2","Molecular Sequence Variation",[59,60,61],"diabetic nephropaty","precision medicine","kidney biopsy","2025-12-17",{"date":64,"type":30},"2025-12-24",{"date":66,"type":30},"2021-08-10",{"date":68,"type":20},"2043-12-31",{"name":70,"class":37},"Herlev Hospital",13,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":38},"100475140","phase-3-safety-outcomes-post-kidney-biopsy---randomized-clinical-evaluation-of-efficacy-of-desmopressin-100475140","NCT05467033","Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin","STOP-BLEED","Inclusion Criteria:\n\n1. ≥ 18 years old\n2. Ability to provide Informed Consent\n3. Qualification by nephrologist to kidney biopsy in accordance to current standards\n4. Initial haemoglobin concentration \\> 8g\u002Fdl and PLT count \\>100 x103\u002FμL\n5. Normal range of APTT and INR\n6. Blood pressure control defined as SBP\\\u003C160 mmHg\n7. Permitted antiplatelet\u002Fantithrombotic drugs: acetylsalicylic acid and heparin\n8. No inflammation at the point of biopsy needle insertion\n\nExclusion Criteria:\n\n1. Initial sodium concentration \\\u003C130mmol\u002Fl\n2. Pregnancy and breastfeeding\n3. Anaphylactic shock after desmopressin administration (medical history)\n4. Necessity of administration other anti-platelet \u002F anti thrombotic drugs other than acetylsalicylic acid, non-fractionated heparin or low molecular weight heparin\n5. Decompensated Heart failure\n6. Von Willebrand disease (VWD) type II B\n7. As per Investigator opinion a medical situation which may lead to increased intracranial pressure (ICP)\n8. Hydronephrosis of the biopsied kidney\n9. Usage of any prohibited drug before screening :\n\n   * ASA in dosage \\> 75mg per day\n   * Vitamin K antagonist (VKA)\n   * Direct oral anticoagulants (DOAC)\n   * Low-molecular-weight heparin (LMWH)\n   * Unfractionated heparin (UFH)\n   * Except situation when dosage of listed above drugs will be adjusted in accordance to protocol","99 Years",{"count":81,"type":20},424,"INTERVENTIONAL",[84],"PHASE3","It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.",[25],"2025-05-05",{"date":89,"type":30},"2025-05-08",{"date":91,"type":30},"2022-09-01",{"date":93,"type":20},"2026-08-31",{"name":95,"class":37},"Medical University of Bialystok"]